Epstein-Barr virus nuclear antigen-1 and myc cooperate in lymphomagenesis

International Journal of Cancer

Volumn 106, Issue 3, 2003, Pages 388-395

  Drotar, Mark E ^a   Silva, Santiago ^b   Barone, Enrico ^a   Campbell, Donald ^a   Tsimbouri, Penelope ^a   Jurvansu, Jaana ^a   Bhatia, Pardeep ^a   Klein, George ^b   Wilson, Joanna B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

B cell; BL; C myc; EBNA 1; EBV; Lymphoma; N myc; Transgenic mice

Indexed keywords

CELL NUCLEUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURKITT LYMPHOMA; CHROMOSOME 15; CONTROLLED STUDY; CROSS BREEDING; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC SELECTION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRANSPOSON; TRISOMY; VIRUS CARCINOGENESIS;

ANIMALS; B-LYMPHOCYTES; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CHROMOSOMES; CROSSES, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; HERPESVIRUS 4, HUMAN; HUMANS; KARYOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA, NEOPLASM; TRANSLOCATION, GENETIC; TRISOMY;

EID: 0038505599     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11224     Document Type: Article

References (52)

1. IARC. Monographs on the evaluation of carcinogenic risks to humans. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. WHO, 1997.
2. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-3.
3. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe PM, Howley PM. Fields virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996.
4. Nishikura K, ar-Rushdi A, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. Proc Natl Acad Sci USA 1983;80: 4822-6.
5. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987;238:1272-5.
6. Strobl LJ, Kohlhuber F, Mautner J, Polack A, Eick D. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift. Oncogene 1993;8:1437-47.
7. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-8.
8. Suda Y, Aizawa S, Hirai S, Inoue T, Furuta Y, Suzuki M, Hirohashi S, Ikawa Y. Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumors, myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumors in transgenic mice. EMBO J 1987;6:4055-65.
9. Schmidt EV, Pattengale PK, Weir L, Leder P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B cell lymphoma model. Proc Natl Acad Sci USA 1988;85:6047-51.
10. Butzler C, Zou X, Popov AV, Bruggemann M. Rapid induction of B cell lymphomas in mice carrying a human IgH/c-mycYAC. Oncogene 1997;14:1383-8.
11. Dildrop R, Ma A, Zimmerman K, Hsu E, Tesfaye A, DePinho R, Alt FW. 1gH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. EMBO J 1989;8:1121-8.
12. Rosenbaum H, Webb E, Adams JM, Cory S, Harris AW. N-myc transgene promotes B lymphoid proliferation, elicits lymphomas and reveals cross-regulation with c-myc. EMBO J 1989;8:749-55.
13. Palomo C, Zou X, Nicholson IC, Butzler C, Bruggemann M. B cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc trans locus is independent of the heavy chain intron enhancer (Eμ). Cancer Res 1999;59:5625-8.
14. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, et al. Burkitt lymphoma in the mouse. J Exp Med 2000;192:1183-90.
15. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-51.
16. Gregory CD, Rowe M, Rickinson AB. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 1990;71:1481-95.
17. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue [published erratum appears in Blood 1998;91:3091]. Blood 1998;91:1373-81.
18. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 1994;68:6069-73.
19. Chodosh J, Holder VP, Gan YJ, Belgaumi A, Sample J, Sixbey JW. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth- transformed cell phenotype. J Infect Dis 1998;177:1194-201.
20. Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999;73:9827-31.
21. Maruo S, Nanbo A, Takada K. Replacement of the Epstein-Barr virus plasmid with the EBER plasmid in Burkitt's lymphoma cells. J Virol 2001;75:9977-82.
22. Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 1992;182:375-84.
23. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996;15:3117-26..
24. Kube D, Vockerodt M, Weber O, Hell K, Wolf J, Haier B, Grässer FA, Müller-Lantzsch N, Kieff E, Diehl V, Tesch H. Expression of Epstein-Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol 1999;73: 1630-6.
25. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol 1999;73:2974-82.
26. Chittenden T, Lupton S, Levine AJ. Functional limits of oriP, the Epstein-Barr virus plasmid origin of replication. J Virol 1989;63: 3016-25.
27. Ceccarelli DF, Frappier L. Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus. J Virol 2000;74:4939-48.
28. Wu H, Ceccarelli DF, Frappier L. The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1. EMBO Rep 2000;1:140-4.
29. Reisman D, Sugden B. Transactivation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986;6:3838-46.
30. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989;63:2644-9.
31. Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 1995;69:2633-6.
32. Tsimbouri P, Drotar ME, Coy JL, Wilson JB. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EμEBNA-1 transgenic mouse lymphocytes. Oncogene 2002;21:5182-7.
33. Reik W, Weiher H, Jaenisch R. Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences. Proc Natl Acad Sci USA 1985;82:1141-5.
34. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990;61:1315-27.
35. Wilson JB, Drotar ME. Considerations in generating transgenic mice: DNA, RNA and protein extractions from tissues - rapid and effective blotting. Epstein-Barr virus protocols. In: Wilson JB, May GHW, eds. Methods in molecular biology. Totowa, NJ: Humana Press, 2001. 361-77.
36. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B cell leukemia prenatally. Mol Cell Biol 1991;11:1176-9.
37. Sabath DE, Broome HE, Prystowsky MB. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 1990;91:185-91.
38. Banerji J, Olson L, Schaffner W. A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell 1983;33:729-40.
39. Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Müller-Lantzsch N. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994;84:3792-8.
40. Lindstrom MS, Klangby U, Wiman KG. P14arf homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001;20:2171-7.
41. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999;13:2658-69.
42. Linardopoulos S, Silva S, Klein G, Balmain A. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc or N-myc transgenes. Int J Cancer 2000;88:920-7.
43. Berns A, van der Lugt N, Alkema M, van Lohuizen M, Domen J, Acton D, Allen J, Laird PW, Jonkers J. Mouse model systems to study multistep tumorigenesis. Cold Spring Harb Symp Quant Biol 1994; 59:435-47.
44. Cuypers HT, Selten GC, Zijlstra M, de Goede RE, Melief CJ, Berns AJ. Tumor progression in murine leukemia virus-induced T cell lymphomas: monitoring clonal selections with viral and cellular probes. J Virol 1986;60:230-41.
45. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
46. Marin MC, Hsu B, Stephens LC, Brisbay S, McDonnell TJ. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res 1995;217:240-7.
47. rd. Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science 1987;235:787-9.
48. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991;65:737-52.
49. Berns A. Tumorigenesis in transgenic mice: identification and characterization of synergizing oncogenes. J Cell Biochem 1991;47:130-5.
50. van Lohuizen M, Breuer M, Berns A. N-myc is frequently activated by proviral insertion in MuLV-induced T cell lymphomas. EMBO J 1989;8:133-6.
51. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989;56:673-82.
52. Srinivas SK, Sixbey JW. Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol 1995;69:8155-8.